Akebia Therapeutics (AKBA) Reports In-Line Q3 EPS

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $40.12 million versus the consensus estimate of $49.18 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• Crown Crafts (CRWS) Reports Q4 EPS of $0.03
• NXP Semiconductors names Mike Lucarelli as new investor relations head